Published in final edited form as:

Biochem Biophys Res Commun. 2013 February 15; 431(3): 566–571. doi:10.1016/j.bbrc.2013.01.015.

Cardiac progenitor-derived Exosomes protect ischemic myocardium from acute ischemia/reperfusion injury

Lijuan Chen^{1,2}, Yingjie Wang^{2,3}, Yaohua Pan², Lan Zhang², Chengxing Shen⁴, Gangjian Qin⁵, Muhammad Ashraf⁶, Neal Weintraub², Genshan Ma¹, and Yaoliang Tang²

¹ Department of Cardiology, Zhongda Hospital, Medical school of Southeast University, Nanjing 210009, China

² Cardiovascular disease, Internal Medicine, University of Cincinnati, 231 Albert Sabin way, Cincinnati, OH 45267

³ Internal Medicine of Traditional Chinese Medicine, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China

⁴ Department of Cardiology, Xinhua Hospital, Shanghai Jiao Tong University, Shanghai, China

⁵ Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL 60611

⁶ Pathology & Lab Med, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267

Abstract

Background—Cardiac progenitors (CPC) mediate cardioprotection via paracrine effects. To date, most of studies focused on secreted paracrine proteins. Here we investigated the CPC-derived-exosomes on protecting myocardium from acute ischemia/reperfusion (MI/R) injury.

Methods and Results—CPC were isolated from mouse heart using two-step protocol. Exosomes were purified from conditional medium, and confirmed by electron micrograph and Western blot using CD63 as a marker. qRT-PCR shows that CPC-exosomes have high level expression of GATA4-responsive-miR-451. Exosomes were ex vivo labeled with PKH26. We observed exosomes can be uptaken by H9C2 cardiomyoblasts with high efficiency after 12 hours incubation. CPC-exosomes protect H9C2 from oxidative stress by inhibiting caspase 3/7 activation in vitro. In vivo delivery of CPC-exosomes in an acute mouse myocardial ischemia/reperfusion model inhibited cardiomyocyte apoptosis by about 53% in comparison with PBS control ($p < 0.05$).

Conclusion—Our results suggest, for the first time, the CPC-exosomes can be used as a therapeutic vehicle for cardioprotection, and highlights a new perspective for using non-cell exosomes for cardiac disease.

© 2013 Elsevier Inc. All rights reserved.

Corresponding authors: Yaoliang Tang MD, Ph.D Associate Professor of Medicine, Division of Cardiovascular Disease College of Medicine, University of Cincinnati 231 Albert Sabin Way, ML0542 Cincinnati, OH 45267 Tel: (513)558-3091 tangyg@ucmail.uc.edu Or Genshan Ma MD magenshan@hotmail.com.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

cardiac progenitors; MicroRNA; Exosomes; ischemia/reperfusion; apoptosis

Introduction

Acute myocardial ischemia/reperfusion (MI/R) injury leads to cardiomyocyte apoptosis and death. Cardiac progenitor cells (CPC) derived from adult heart have emerged as one of the most promising stem cell types for cardioprotection and repair[1-5]. The therapeutic effect of CPC can be attributed to both cardiovascular lineage differentiation and paracrine effects[6-8].

Stem cells can secrete exosomes, the 40–100 nm size membrane vesicles containing microRNA (miRNA)[9, 10]. miRNA are evolutionarily conserved, 18–25 nucleotide, nonprotein coding transcripts that control gene expression via post-transcriptional repression[11, 12]. In stem cells, miRNAs play significant roles in modulating differentiation[13], proliferation[14], and apoptosis[15]. Increasing evidence suggested that exosomes play an important role for miRNA communication between donor cells and recipient tissues[16, 17], and exosomes mediated paracrine effect might be a novel mechanism for beneficial effect of CPC transplantation.

Exosomes from bone marrow derived mesenchymal stem cell (MSC) have been reported to reduce myocardial ischemia/reperfusion injury ex vivo[18], CPC express high level of early cardiac specific transcription factors, such as GATA4, Mef2c, Isl1, et al[19-21], however, there is no report about whether exosomes secreted by CPC can protect myocardium from acute myocardial ischemia/reperfusion injury.

In this study, we show that the administration of purified CPC-exosomes can efficiently protects cardiomyocytes from oxidative induced apoptosis in vitro and acute myocardial apoptosis in mouse models of acute MI/R.

Methods

All experimental procedures were performed in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of University of Cincinnati.

Isolation of cardiosphere derived cells

Cardiac progenitors were generated from the hearts of 2-month-old, male, C57BL/6 mice (The Jackson Laboratory, Bar Harbor, Maine) isolated via a 2-step procedure as described previously[5, 22]. Briefly, in step 1, cardiac explants were minced and cultured for 2-3 weeks until the small, round, phase-bright cells migrated from the adherent explants and proliferated over a fibroblast layer. In step 2, Sca-1+ cells were isolated from the phase-bright cells through magnetic-activated cell sorting (MACS) with Sca-1 magnetic beads (Miltenyi Biotec Inc., Auburn, CA) as instructed by the manufacturers' protocols. The selected Sca-1 cells were cultured and maintained in complete media containing DMEM/F12, 10% exosomes-removed fetal calf serum (Exo-FBS, System Biosciences (SBI), Mountain View, CA), 200 mM L-glutamine, 55 nM β -mercaptoethanol, and 1% MEM nonessential amino acids.

Exosome purification

The CPC-exosome isolation procedures were performed at 4°C as described in the literatures with modification[23]. Briefly, 10 ml culture medium (CM) with 2% exosome-removed FBS was used for culturing 5×10^5 CPC in 10 cm dish. After 48hrs, supernatant was centrifuged at 1000r.p.m. for 10min to eliminate cells, followed by filtration through 0.22µm filter to remove cell debris. Exosomes in medium were precipitated with 1/3 volume of polyethylene glycol (PEG) buffer (33.4% PEG 4000, 50 mM HEPES (pH 7.4), 1 M NaCl) overnight at 4°C followed by centrifugation at 3,000 rpm for 30 min and resuspension in 50 µl of PBS and stored at -80°C.

Electron microscopy

For the transmission electron microscopy (TEM) morphology investigation, 3µl of exosome pellet was placed on formvar carbon-coated 200-mesh copper electron microscopy grids, and incubated for 5min at room temperature (RT), and then was subjected to standard uranyl acetate staining[24]. The grid was washed with three changes of PBS and allowed to semi-dry at room temperature before observation in transmission electron microscope (Hitachi H7500 TEM, Tokyo, Japan). Micrographs were used to quantify the diameter of exosomes.

Isolation and Quantification of microRNAs

Total RNA from CPC or isolated CPC-exosomes were extracted by RNeasy RT (Molecular Research Center, Inc. Cincinnati, OH) following the manufacturer's instructions. Isolated RNAs were polyadenylated using the Ncode miRNA first-strand cDNA synthesis kit (Invitrogen). The cDNA synthesized was used to perform quantitative PCR on an Mx3000P Real-Time PCR System (Agilent Technologies, Santa Clara, CA) using the SensiMix SYBR kit (Bioline, Tauton, MA). Amplification was performed at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 60°C for 1min.

For mature miRNA expression: the universal primer provided in the NCode™ miRNA first-strand cDNA synthesis kit was used together with one of the following forward primer:

Mmu-miR-144: 5'TAC AGT ATA GAT GAT GTA CT3'

Mmu-miR-451: 5' AAA CCG TTA CCA TTA CTG AGT T 3'

Mmu-miR-U6: 5' ACA CGC AAA TTC GTG AAG C 3'

Fold-induction was calculated using the Ct method: $\Delta\Delta Ct = (Ct_{\text{Target miRNA}} - Ct_{U6})_{\text{exosomes}} - (Ct_{\text{Target miRNA}} - Ct_{U6})_{\text{CPC}}$, and the final data were derived from $2^{-\Delta\Delta Ct}$

Western blotting

Exosome lysate supernatants were prepared, exosomes were assessed for their protein content using BCA Protein Assay Kit (Pierce, Rockford, IL), and then resolved on a 7%–12% sodium dodecyl sulfate bis-tris gel, and transferred to an Immobilon® FL PVDF membrane (Millipore, Billerica, MA). For Odyssey technology, the membrane was blocked with Odyssey blocking buffer (LICOR Biosciences, Lincoln, NE) and probed with rabbit anti-CD63 (1:250, SC-15363, Santa Cruz Biotechnology, Inc., Santa Cruz, CA)), and then, IRDye 680 goat anti-rabbit IgG at 1:5,000 (LICOR Biosciences). Probed blots were scanned using an Odyssey infrared imager.

H9C2 treat with CPC exosomes and caspase assay

H9C2 cardiomyoblasts were obtained from American Type Culture Collection (Rockville, MD) and cultured in DMEM medium supplemented with 10% FBS, 100 U/mL penicillin,

and 100 µg/mL streptomycin. H9C2 cells were pre-incubated with 2% Exo-FBS DMEM with or without CPC-exosomes for 24 hrs, then incubated with 200 µM H₂O₂ for 4 h. Following treatment, activity of CASPASE-3 and -7 in H9C2 was assayed with Caspase-Glo 3/7 Assay System (Promega, Madison) according to the instructions of the manufacturer.

Exosome Labeling with PKH26

Purified CPC-exosomes were labeled with PKH26 red fluorescent labeling kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer's instructions. The PKH26 concentration for exosome labeling is 2×10^{-6} M per exosomes from 5×10^5 cells. The labeled exosomes were stained with PKH26 dye in 400ul Diluent C fluid supplied with the kit for 5 minutes at room temperature, an equal volume of serum was added to stop the labeling, the exosomes were re-purified via PEG precipitation. The labeled CPC-exosomes were incubated with H9C2 for 12hrs at 37°C, washed with PBS, the uptake of labeled exosomes by H9C2 was determined using an inverted fluorescence microscope.

Murine Myocardial Ischemia-Reperfusion Model

The mice were subjected to myocardial ischemia/reperfusion as described previously[25]. Briefly, male C57BL/6 mice weighing 25 to 30 g were anesthetized with intraperitoneal 100mg/kg ketamine combined with 10mg/kg xylazine. Mice were intubated transorally with a 24-gauge tube, and ventilated with oxygen-enriched room air using a Harvard rodent ventilator (Inspira Advanced Safety Ventilator Model 55–7058, Holliston, MA). The chest was opened via a lateral thoracotomy, and the heart was exposed through pericardiotomy. An 8-0 nylon suture (Ethicon, Somerville, NJ) was placed under the left anterior descending artery (LAD) and then threaded through a small plastic (PE10) tube to form a snare for reversible left coronary artery occlusion.

The left coronary artery was occluded for 45 minutes, and then reperfusion was effected by gently removing the tube. The chest was closed and the mice allowed recovering. Animals were sacrificed at 24 hours after reperfusion histology assay.

Intramyocardial Delivery of CPC-exosomes into Hearts

Myocardium exosome delivery was performed on mice immediately after induction of ischemia by LAD ligation. The mice were assigned to two groups based upon the injection (n = 6 per group):

1. PBS group: intramyocardial delivery of 25ul PBS with MIR.
2. CPC-exosomes group: intramyocardial delivery of 25ul exosomes from 5×10^5 CPC with MIR.

Histology

To quantify apoptotic cardiomyocytes, mouse hearts were removed 24 h after myocardial reperfusion, fixed with 30% sucrose, and routinely frozen embedded in OCT and processed for sectioning and staining with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and cardiac Troponin I (cTnI) (1:50; sc-15368, Santa Cruz Biotechnology, Santa Cruz, CA). TUNEL was performed using The DeadEnd™ Fluorometric TUNEL System (Promega) per the manufacturer's protocol. The slides were incubated with Alexa 555-conjugated anti-rabbit secondary antibodies (Invitrogen). Slides were mounted using VECTASHIELD HardSet Mounting Medium with DAPI (Vector Laboratories). The staining was analyzed by a Zeiss 710 Laser Scanning Microscope (Carl Zeiss, Thornwood, NY). Apoptotic cardiomyocytes was quantified and classified as a TUNEL-positive cTnI-positive in a given field (×20).

Statistical Analysis

All values are expressed as mean $\pm$ standard error of mean (SEM). Student's t-test was used to compare two groups. A value of $p < 0.05$ was considered to indicate statistically significant differences.

Results

Characterization of CPC-exosomes isolated by PEG precipitation

CPC were obtained with a two-step procedure: cardiospheres were grown from enzymatically-digested minced mouse adult heart and expanded, then the CPC cells were isolated by using a hematopoietic lineage-depletion cocktail followed by enrichment for Sca-1+ cells via MACS sorting (**Fig. 1A**). RT-PCR shows that CPC over express cardiac transcription factor, GATA4 while bone marrow derived mesenchymal stem cell (BM-MSC) do not express GATA4 (**Fig. 1B**). To character the CPC-exosomes, we first monitored the release of exosomes in conditioned media of mouse CPC. Exosomes were readily detectable in conditioned media from CPC after PEG precipitation (**Fig. 1C**). Morphological analysis of the CPC-exosomes using electron micrography revealed a heterogeneous population of vesicles comprising both round-shaped 40–100 nm diameter vesicles (**Fig. 1D**), Western blot analysis of CPC-exosomes revealed the presence of exosome marker CD63 (**Fig. 1E**).

Exosome labeling and uptake of exosomes by H9C2

To determine whether CPC-exosomes can be taken up by cardiomyocytes, we labeled CPC-exosomes with PKH26, a fluorescent cell linker compound that is incorporated into the cell membrane by selective partitioning. After labeling, the exosome pellet show strong red color. When we incubated exosomes labeled with PKH26 with H9C2, we observed a red fluorescence in the cytoplasm in almost every H9C2 (**Fig. 2A**), indicating that significant amounts of exosomes were taken up by the H9C2.

Effects of CPC-exosomes on H2O2-induced apoptosis in H9C2 cells

In order to determine the effects of exosomes on oxidative stress-induced myocyte apoptosis, the H9C2 cells were pretreated with exosomes or PBS in medium with 2% Exo-FBS for 24 h, and then coincubated with 200 μ M of H2O2 for additional 4 h. Caspases-3/7 are executioner for the death program in many cells in response to oxidative stress, such as H2O2. Thus we examined the effect of CPC-exosomes on H2O2-stimulated caspase-3/7 activation, we compared Caspase 3/7 activity in H2O2-treated cells with or without CPC-exosomes. As shown in **Fig. 2B**, CPC exosomes pretreatment significantly decreased the levels of caspase-3/7 activity in H2O2-treated H9C2, indicating that CPC-exosomes attenuated H2O2-induced apoptosis.

In vivo delivery of CPC-exosomes inhibits apoptosis in a mouse acute ischemia-reperfusion model

Apoptotic signals are induced in cardiomyocytes after acute ischemia/reperfusion. To determine whether CPC-exosomes treatment could inhibit ischemia/reperfusion-induced apoptosis of cardiomyocytes in vivo, we combined TUNEL labeling with the cardiomyocyte marker cTnI on reperused mouse hearts treated with CPC-exosomes or control PBS. Delivery of CPC-exosomes to myocardium with ischemia-reperfusion produced a 53% reduction of the TUNEL apoptotic cells in reperfusion myocardium compared with the PBS control hearts ($13 \pm 1.5\%$ in PBS group vs $6.1 \pm 0.8\%$ in CPC-exosome group, $P < 0.05$, respectively), indicating that exosomes from CPC could obviously inhibit apoptosis induced by ischemia-reperfusion injury in myocardium (**Fig. 3 A-C**).

Differential miR-451 content in CPC-exosomes vs. CPC

Recent studies suggest that intercellular transfer of miRNAs by exosomes is able to modulate gene expression in recipient cells. CPC are progenitor cells with high level of GATA4 expression (**Fig. 1B**). The miR-144/451 cluster, an important GATA4-responsive miRNA cluster, has been reported to protect ischemic cardiomyocytes from mimic ischemia/reperfusion injury in vitro. To evaluate whether exosomes secreted by CPC can carry GATA4-responsive, cardioprotective miRNAs, we isolated exosomes from cell supernatants of the CPC. Exosomes were isolated by a series of microfiltration and PEG precipitation steps. We quantified relative levels of a miRNA-144/451 in CPC-derived exosomes and CPC. We found that miR-451 was significantly enriched in CPC-derived exosomes vs CPC, in contrast, miR-144 was more highly represented in CPC than in CPC-exosomes (**Fig. 4**), suggesting a distinct microRNA enrichment character of CPC-derived exosomes.

Discussion

This is the first observation that exosomes derived from CPC can protect cardiomyocytes from oxidative stress in vitro and ischemia-reperfusion injury in vivo. In our experiment, we found that PKH26, a fluorescent cell membrane linker compound, can be used to label exosomes, and cardiomyocytes can take up exosomes at high efficiency. We also found that miR-451, one of the GATA4-responsive miRNA in miR-144/451 cluster, is enriched in CPC-exosomes while miR-144 is absent in CPC-exosomes. CPC-exosomes might provide a promising non-cellular approach for cardioprotection in patients with high risk of ischemic attack.

We have reported that CPC transplantation ameliorates the deleterious consequences of myocardial ischemia [5]. We found that transplantation of stem cells into ischemic myocardium decreased apoptosis [26-28]. Some of these beneficial effects can be better explained by a paracrine mechanism than by stem cell differentiation [28]. We have previously performed an unbiased antibody cytokine array analysis, and observed that CPC secreted higher levels of numerous factors, including chemokines (e.g., TCA-3, SDF-1, 6CKine), vascular growth factors (e.g., VEGF, osteopontin, bFGF, erythropoietin, stem-cell factor), and factors involved in cardiac differentiation (e.g., Activin A, TGF- β , and Dickkopf homolog-1) that could potentially repair injured cardiac tissue mainly through endogenous stem cell homing and activation [5]. However, the paracrine effects of CPC may not be totally contributed to soluble cytokines. In addition to cytokines, exosomes is a lipid vesicle, which represents an ideal vehicle to deliver genetic materials, such as miRNAs, from one cell to another, and execute their functions [17]. Our observations demonstrated that exosomes with a diameter of 40–100 nm are present in the conditional medium of CPC and are therefore the major cardioprotective component in the conditional medium. We confirmed that the purified exosomes from conditioning medium of CPC, other than small soluble proteins, can protect H9C2 from apoptosis induced by H₂O₂ mediated oxidative stress, and enhance cardiomyocytes against apoptosis induced by acute myocardial ischemia/reperfusion.

Our findings demonstrated that the CPC-derived exosomes contained high level of miR-451 in comparison with CPC. Studies in rodents demonstrate that microRNA-144/451 (miR-144/451) cluster is regulated by GATA-4 [29], a critical transcription factor expressed in early heart development [30]. Recent study demonstrated that miR-451 confers protection against simulated ischemia/reperfusion (I/R)-induced cardiomyocyte death [29], however, miR-144, another GATA4-responsive miRNA within miR-144/451 cluster, is absent in CPC-exosomes. The mechanism why CPC-exosomes only enrich specific miRNA but not another from CPC is unknown, exploring this mechanism might help us optimizing the genetic components inside the exosomes for therapeutic purpose.

In summary, we have identified exosome as the cardioprotective component in CPC mediated paracrine effects. This finding broadens our current understanding of the beneficial paracrine effect of CPC transplantation on heart repair. It also highlights for the first time the important role of CPC-derived exosome as mediator of cardioprotection.

Perspectives

For myocardium with acute ischemia/reperfusion injury, myocardial injury is potential reversible if treated with cardioprotective exosomes early during the critical time window[31]. The CPC-derived exosomes therapy provides a non- cell therapy approach to deliver critical miRNAs to ischemic myocardium for cardioprotection. Since miRNAs are remarkably stable[32], both interventional cardiologists and cardiac surgeons could deliver them into the ischemic myocardium for protecting the heart from ischemia and reperfusion injury.

Acknowledgments

This work was supported by National Natural Science Foundation of China (No. 81270203, to L.C.), the American Heart Association Beginning Grant-in-Aid 0765094Y (to Y.T.); NIH grant HL086555 (to Y.T.), and NIH grants HL076684 and HL62984 (to N.L.W.).

Reference

1. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. *Proceedings of the National Academy of Sciences of the United States of America*. 2003; 100(21):12313–12318. [PubMed: 14530411]
2. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, Salio M, Battaglia M, Latronico MV, Coletta M, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. *Circulation research*. 2004; 95(9):911–921. [PubMed: 15472116]
3. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, Lin LZ, Cai CL, Lu MM, Reth M, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature*. 2005; 433(7026):647–653. [PubMed: 15703750]
4. Linke A, Muller P, Nurzynska D, Casarsa C, Torella D, Nascimbene A, Castaldo C, Cascapera S, Bohm M, Quaini F, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102(25):8966–8971. [PubMed: 15951423]
5. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, Kishore R, Phillips MI, Losordo DW, Qin G. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. *Circulation research*. 2009; 104(10):1209–1216. [PubMed: 19407239]
6. Matsuura K, Honda A, Nagai T, Fukushima N, Iwanaga K, Tokunaga M, Shimizu T, Okano T, Kasanuki H, Hagiwara N, et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. *The Journal of clinical investigation*. 2009; 119(8):2204–2217. [PubMed: 19620770]
7. Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, Mu J, Dai S, Li C, Chen N, Peng Y, et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. *Circulation*. 2010; 121(2):293–305. [PubMed: 20048209]
8. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. *Journal of molecular and cellular cardiology*. 2005; 39(5):733–742. [PubMed: 16199052]
9. Biancone L, Bruno S, Derigibus MC, Tetta C, Camussi G. Therapeutic potential of mesenchymal stem cell-derived microvesicles. *Nephrology, dialysis, transplantation : official publication of the*

- European Dialysis and Transplant Association - European Renal Association. 2012; 27(8):3037–3042.
10. Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer--the emerging science of cellular 'debris'. *Seminars in immunopathology*. 2011; 33(5):455–467. [PubMed: 21318413]
 11. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. *Nature reviews Cardiology*. 2009; 6(6):419–429.
 12. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. *Cell Cycle*. 2007; 6(17):2127–2132. [PubMed: 17786041]
 13. Juan AH, Sartorelli V. MicroRNA-214 and polycomb group proteins: a regulatory circuit controlling differentiation and cell fate decisions. *Cell Cycle*. 2010; 9(8):1445–1446. [PubMed: 20372071]
 14. Brett JO, Renault VM, Rafalski VA, Webb AE, Brunet A. The microRNA cluster miR-106b~25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation. *Aging*. 2011; 3(2):108–124. [PubMed: 21386132]
 15. Glass C, Singla DK. ES cells overexpressing microRNA-1 attenuate apoptosis in the injured myocardium. *Molecular and cellular biochemistry*. 2011; 357(1-2):135–141. [PubMed: 21671035]
 16. Stoorvogel W. Functional transfer of microRNA by exosomes. *Blood*. 2012; 119(3):646–648. [PubMed: 22262739]
 17. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, Bernad A, Sanchez-Madrid F. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nature communications*. 2011; 2:282.
 18. Angoulvant D, Ivanov F, Ferrera R, Matthews PG, Nataf S, Ovize M. Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2011; 30(1):95–102. [PubMed: 21030271]
 19. Xiao J, Liang D, Zhang H, Liu Y, Zhang D, Liu Y, Pan L, Chen X, Doevendans PA, Sun Y, et al. MicroRNA-204 is required for differentiation of human-derived cardiomyocyte progenitor cells. *Journal of molecular and cellular cardiology*. 2012; 53(6):751–759. [PubMed: 22982025]
 20. Nelson TJ, Faustino RS, Chiriac A, Crespo-Diaz R, Behfar A, Terzic A. CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells. *Stem Cells*. 2008; 26(6):1464–1473. [PubMed: 18369102]
 21. Genead R, Danielsson C, Andersson AB, Corbascio M, Franco-Cereceda A, Sylven C, Grinnemo KH. Islet-1 cells are cardiac progenitors present during the entire lifespan: from the embryonic stage to adulthood. *Stem cells and development*. 2010; 19(10):1601–1615. [PubMed: 20109033]
 22. Tang YL, Shen L, Qian K, Phillips MI. A novel two-step procedure to expand cardiac Sca-1+ cells clonally. *Biochemical and biophysical research communications*. 2007; 359(4):877–883. [PubMed: 17577582]
 23. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, Sdrimas K, Fernandez-Gonzalez A, Kourembanas S. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. *Circulation*. 2012; 126(22):2601–2611. [PubMed: 23114789]
 24. Hu G, Yao H, Chaudhuri AD, Duan M, Yelamanchili SV, Wen H, Cheney PD, Fox HS, Buch S. Exosome-mediated shuttling of microRNA-29 regulates HIV Tat and morphine-mediated neuronal dysfunction. *Cell Death Dis*. 2012; 3:e381. [PubMed: 22932723]
 25. Tang YL, Qian K, Zhang YC, Shen L, Phillips MI. A vigilant, hypoxia-regulated heme oxygenase-1 gene vector in the heart limits cardiac injury after ischemia-reperfusion in vivo. *Journal of cardiovascular pharmacology and therapeutics*. 2005; 10(4):251–263. [PubMed: 16382261]
 26. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, Yang YZ, Pan C, Ge J, Phillips MI. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. *Regulatory peptides*. 2004; 117(1):3–10. [PubMed: 14687695]

27. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. *Journal of the American College of Cardiology*. 2005; 46(7):1339–1350. [PubMed: 16198853]
28. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, Phillips MI. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. *The Annals of thoracic surgery*. 2005; 80(1):229–236. discussion 236–227. [PubMed: 15975372]
29. Zhang X, Wang X, Zhu H, Zhu C, Wang Y, Pu WT, Jegga AG, Fan GC. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. *Journal of molecular and cellular cardiology*. 2010; 49(5):841–850. [PubMed: 20708014]
30. Durocher D, Charron F, Warren R, Schwartz RJ, Nemer M. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. *The EMBO journal*. 1997; 16(18):5687–5696. [PubMed: 9312027]
31. Roubille F, Franck-Miclo A, Covinhes A, Lafont C, Cransac F, Combes S, Vincent A, Fontanaud P, Sportouch-Dukhan C, Redt-Clouet C, et al. Delayed postconditioning in the mouse heart in vivo. *Circulation*. 2011; 124(12):1330–1336. [PubMed: 21875909]
32. Creemers EE, Tijssen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circulation research*. 2012; 110(3):483–495. [PubMed: 22302755]

Highlights

- ▶ Cardiac progenitor-derived (CPC) Exosomes protect H9C2 from apoptosis in vitro
- ▶ CPC-exosomes protect cardiomyocytes from MI/R induced apoptosis in vivo.
- ▶ CPC-exosomes were taken up by H9C2 with high efficiency using PKH26 labeling.
- ▶ miR-451, one of GATA4-responsive miRNA cluster, is enriched in CPC-exosomes.

Figure 1.

Characterization of CPC and exosomes from CPC. (A) Mouse cardioprogenitor cells; (B) RT-PCR for mature cardiac marker (TnI) and early cardiac markers (Mesp1, GATA4 and Nkx2.5) in bone marrow derived mesenchymal stem cells (BM-MSC) and CPC. GATA4 mRNA was detected at high level by RT-PCR in CPC while absent in BM-MSC. (C) CPC-exosomes isolated by PEG precipitation; (D) electron micrograph image of CPC-derived exosomes. The image shows small vesicles of approximately 40-100 nm in diameter. Scale bar=100nm. (E) Western blot characterization of CPC-exosomes. CPC-exosome preparation was separated by SDS-PAGE, and electroblotted to the polyvinylidene fluoride (PVDF) membrane, and probed with exosome marker CD63.

Figure 2.

uptake of exosomes by H9C2 and CPC-exosomes protecting H9C2 from H₂O₂ induced apoptosis in vitro (A) Uptake of PKH26-labeled-exosomes by H9C2 in vitro. H9C2 cells incorporated PKH26 labeled-exosomes from CPC after 12hrs incubation. Red dots indicate CPC-exosomes incorporated in H9C2 cells. (B) CPC-exosomes protected H9C2 from H₂O₂ induced apoptosis in vitro. Caspase-3/7 activity assay was used to assess the effect of protection of CPC-exosomes on H9C2 cells treated for 4hs of H₂O₂ (200 μ m). Data shown are mean $\pm$ SEM of 4 independent experiments.

Figure 3.

Immunohistochemistry of control PBS or CPC-exosomes-treated heart sections marking TUNEL-positive cardiomyocytes costained with cardiac troponin I antibody within the border zone of infarcted hearts. (A and B) Representative illustration of TUNEL staining in heart section after 45min ischemia and 24h reperfusion. (C) Quantification of myocardial apoptosis. Green staining indicates TUNEL-positive cells, red staining indicating cTnI positive cardiomyocytes, Error bars indicate SEM (*, $P < 0.05$).

Figure 4.

Real-time RT-PCR validation of differential expression of miR-451 and miR-144 in CPC-exosomes versus CPC. U6 snRNA was used as a normalization reference in real-time PCR